Author

N. Wentworth-Hartung

Observed names: N. L. Wentworth-Hartung, Nicole Lea Wentworth-Hartung, Nicole Wentworth-Hartung

Institution: Metro-Minnesota Community Oncology Research Consortium

Observed institutions: Metro-Minnesota Community Oncology Research Consortium, Minnesota Oncology

OpenAlex ID: A5013168695

Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)

2010 · Aminah Jatoi, Abby Thrower, et al. · The Oncologist · 57

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

2013 · John W. Smith, Svetislava Vukelja, et al. · Breast Cancer Research and Treatment · 13

Preliminary Toxicity Results of a Phase II Randomized Trial of Weekly or Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC).

2009 · J. Smith II, J. Smith II, et al. · Cancer Research · 9

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.

2011 · S. Attia, M. R. Mahoney, et al. · Journal of Clinical Oncology · 8

Works count: 5

Citation count: 96

H-index: 5

I10-index: 2